Piperacillin Inj Rx
Generic Name and Formulations:
Piperacillin sodium 2g, 3g, 4g; per vial; pwd for IM or IV inj after reconstitution; IV infusion after reconstitution and dilution; sodium content 42.5mg/g piperacillin sodium.
Various generic manufacturers
Indications for Piperacillin Inj:
Serious susceptible infections, including lower respiratory tract, intraabdominal, septicemia, skin and skin structure, bone and joint, UTIs, gynecological infections, and uncomplicated gonoccocal urethritis. Surgical prophylaxis in intraabdominal (GI and biliary) procedures, vaginal and abdominal hysterectomy, and cesarean section.
Give by IM inj into upper outer quadrant of buttock; or IV inj over 3–5 minutes; or IV infusion over 20–30 minutes. Max dose: 24g/day. IM inj: max 2g per injection site. May give 1g probenecid orally ½ hour prior to inj. Serious infections: 12–18g/day IV (200–300mg/kg/day) in divided doses every 4–6 hours. Complicated UTIs: 8–16g/day IV (125–200mg/kg/day) in divided doses every 6–8 hours. Uncomplicated UTIs and community-acquired pneumonia: 6–8g/day IM or IV (100–125mg/kg/day) in divided doses every 6–12 hours. Uncomplicated gonorrhea infections: 2g IM once as a single dose. All: treat for 7–10 days; gynecological infections: 3–10 days; Streptococcus pyogenes infections: at least 10 days. Acute infections: continue therapy 48–72 hours after patient becomes asymptomatic. Prophylaxis, renal impairment, or hemodialysis: see literature.
Beta-lactam allergy including cephalosporins.
Renal impairment. Salt-restricted. Monitor renal, hepatic, hematopoietic function in prolonged use. Discontinue if bleeding disorder occurs. Cystic fibrosis (increased fever/rash risk). Gonorrhea infections: do serologic test for syphilis at baseline and 3 months after therapy. Pregnancy (Cat.B). Nursing mothers.
Potentiated by probenecid. Antagonizes aminoglycosides. May potentiate non-depolarizing muscle relaxants (eg, vercuronium). Monitor methotrexate, heparin, anticoagulants. May cause false (+) with Clinitest, Benedict's or Fehling's soln, Coomb's test.
Inj site reactions, GI disturbances, rash (may be severe, eg, Stevens-Johnson syndrome), headache, dizziness, fatigue, seizures, renal impairment, anaphylaxis, blood dyscrasias, bleeding.
Formerly known under the brand name Pipracil.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|